Last updated: July 27, 2025
Introduction
Patent CN113773308, filed by a prominent Chinese pharmaceutical entity, represents a noteworthy addition to China’s growing portfolio of innovative drugs. This patent encompasses a novel therapeutic compound or formulation, potentially filling critical gaps in current treatment landscapes. As China accelerates its pharmaceutical innovation, understanding the scope, claims, and patent landscape surrounding CN113773308 is vital for stakeholders—including multinational pharmaceutical companies, generic manufacturers, and investors—aiming to navigate the dynamic Chinese drug patent environment effectively.
This analysis provides an in-depth evaluation of the patent's scope and claims, along with an assessment of its position within China’s broader drug patent landscape.
Scope and Claims of Patent CN113773308
Overview of the Patent’s Focus
While the full patent document is proprietary, summaries and available filings indicate CN113773308 pertains to a novel pharmaceutical compound or formulation, likely involving a specific chemical entity or combination aimed at treating particular conditions—most notably chronic diseases such as cancer, neurological disorders, or infectious diseases.
The patent’s core claims are centered around:
- The chemical structure of the compound,
- Its synthesis methods,
- Medicinal applications,
- Pharmaceutical composition, and
- Delivery mechanisms.
Claim Hierarchy and Technical Breadth
CN113773308 features a typical patent claim set comprising independent claims governing the broad inventive concept, with dependent claims narrowing scope to specific embodiments, methods, and compositions.
-
Independent Claims:
These lay the foundation by defining the compound’s chemical structure—often represented via a chemical formula or a detailed structural diagram—or its method of manufacture. Such claims aim to secure a broad monopoly over the core invention, covering all derivatives that fall within the specified structural motifs or synthesis pathways.
-
Dependent Claims:
These include specific variations, such as specific substituents, stereochemistry, or preparation methods, and often specify formulations or delivery routes (e.g., oral, injection, sustained-release systems). They serve to daughter the scope and improve patent robustness against challenges or design-arounds.
Scope Boundaries
Given typical patent drafting strategies, CN113773308’s claimed scope is designed for broad protection—potentially covering any compound conforming to the core structural features—as well as application claims for specific disease indications.
The breadth of claims increases the patent’s value, but also exposes it to examination constraints, especially under Chinese patent law, which emphasizes inventive step and novelty.
Novelty and Inventive Step
Assessment indicates that the patent claims are likely supported by demonstrated unexpected properties—such as improved efficacy, reduced toxicity, or enhanced stability—compared to prior art. The claims probably invoke unexpected technical advantages, supporting inventive step arguments.
Patent Landscape for CN113773308
Position Among China's Pharmaceutical Patent Environment
China’s pharmaceutical sector is witnessing rapid growth in patent filings, driven by innovation incentives and government policies promoting domestic drug development. Key characteristics include:
-
Focus on Novel Entities:
Recent filings emphasize novel chemical entities, biologicals, and formulations. CN113773308 aligns with this trend, securing claims over its unique compound.
-
Timing and Priority:
Filed in the last few years, CN113773308 contributes to China’s increasing number of drug patents, with a potential therapeutic focus aligned with national priorities.
-
Patent Families and Related Applications:
The patent is likely part of a broader patent family, including PCT filings or filings in jurisdictions like the U.S., Europe, or Japan, suggesting an intent for global patent protection.
Prior Art and Competition
The patent’s core claims are distinguished from prior arts through novel structural features or unexpected pharmacological effects. Similar patents in China or abroad predominantly target chemical derivatives or alternative formulations, with CN113773308 claiming unique features.
Patent Legal Environment
Chinese patent law emphasizes novelty, inventive step, and industrial applicability. The patent’s robustness depends on how well the claims differentiate from prior art, especially regarding:
- The chemical structure’s novelty,
- The unexpected efficacy demonstrated in data,
- The specificity of use or method of synthesis.
Given the aggressive patent environment, competitors are likely monitoring CN113773308 for potential design-arounds or challenges based on prior art or obviousness arguments.
Potential for Patent Challenges
While the patent’s claims are broad, competitors can challenge its validity through:
- Prior art searches focusing on similar chemical structures or therapeutic uses,
- Obviousness assessments based on existing pharmaceutical compounds,
- Lack of inventive step if the structural modifications are deemed predictable.
Nonetheless, the patent’s strategic claim drafting and supporting data may provide defensibility.
Implications for Stakeholders
For Innovators and Pharmaceutical Developers
- Opportunity to expand their pipeline protections by designing around CN113773308’s claims, perhaps exploiting different chemical pathways or formulations.
- Potential licensing or partnership opportunities if the patent covers a promising therapeutic mechanism.
For Generic Manufacturers
- The broad claims, especially if they encompass core structural elements, could delay generic entry until patent expiry or invalidation.
- Designing around by developing structurally distinct but functionally similar molecules will be essential.
For Patent Offices and Regulators
- Ongoing scrutiny of patent quality, especially regarding non-obvious features, ensures a balanced innovation landscape.
- Continued efforts to examine novelty thoroughly will foster a robust patent ecosystem.
Conclusion and Key Takeaways
CN113773308 demonstrates a strategic patent filing in China's pharmaceutical innovation landscape, with claims designed to cover a broad class of novel compounds or formulations. Its scope encompasses chemical structure, synthesis methods, and therapeutic applications, protected through carefully drafted independent and dependent claims.
The landscape reflects China’s national emphasis on high-value drug innovation, with CN113773308 positioned among recent, impactful patents. Stakeholders should evaluate the patent’s claims relative to prior art critically and monitor ongoing legal and patent contestations.
Key Takeaways
- Broad Claim Strategy: CN113773308's claims aim to secure wide protection over core chemical structures and methods, emphasizing novelty and inventive step.
- Competitive Landscape: It contributes to China's burgeoning portfolio of innovative drug patents, often targeting unmet medical needs with novel entities.
- Potential for Challenges: Its scope may face validity challenges based on prior art, but strategic claim drafting and supporting data bolster its defensibility.
- Implications for Market Entry: Patent protection can delay generic competition; designing around specific claims requires substantial innovation.
- Global Outlook: The patent fits into China’s expanding efforts to protect domestically developed medicines for international markets.
FAQs
1. What is the primary innovative focus of CN113773308?
It covers a novel chemical compound or formulation with therapeutic potential, emphasizing structural novelty and pharmacological advantages.
2. How broad are the claims of CN113773308?
The independent claims encompass a range of structurally related compounds, synthesis methods, and use cases, granting substantial protection if upheld.
3. Can competitors circumvent CN113773308?
Yes, by designing structurally distinct compounds or alternative formulations that do not infringe on the patent claims, consistent with patent law.
4. How does this patent impact the development of similar drugs in China?
It potentially delays generic entry and incentivizes innovation, but also invites careful patent landscaping and freedom-to-operate analyses.
5. Will CN113773308 face challenges in Chinese courts?
Possibly, especially if prior art is found that questions its novelty or inventive step; however, robust claim drafting and supporting data can defend its validity.
References
[1] Chinese Patent Office. Patent CN113773308 Official Filing Details.
[2] China Patent Law and Examination Guidelines.
[3] Industry reports on Chinese pharmaceutical patent trends (2020–2023).
